 |
Prospector
Profile
07.1057
|
| |
| Immtech Pharmaceuticals, Inc. |
NAICS |
541710 |
| One North End Avenue
New York, NY 10282 |
Description |
Biotechnology |
| (847) 573-0033 |
Employees |
27 |
| http://www.immtechpharma.com/ |
Revenue |
(mil) |
4.3180 |
| |
Income |
(mil) |
-11.1320 |
| |
Assets |
(mil) |
19.1440 |
| |
Liability |
(mil) |
4.6870 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Immtech Pharmaceuticals, Inc. reported a net loss of $11,683,199 on revenues of $4,318,013 for the year ended March 31, 2007, much lower than the net loss reported last year of $16,289,710 on revenues of $3,575,042. The Company continuing losses resulted to an accumulated deficit of $100,525,287 in its March 31, 2007 balance sheet.
|
| |
|
Intellectual Property:
The Company's pharmaceutical compounds, including pafuramidine, are protected by multiple patents secured by its research partners. The Company considers the protection of proprietary technologies and products to be important to its business. It relies on a combination of patents, licenses, copyrights and trademarks to protect these technologies and products. Protection of aromatic cation technology platform includes exclusive licensing rights to 204 patents and patent applications, 104 of which have issued in the United States and in various global markets. It also owns separately 6 issued patents. [SEC Filing 10-K 06-13-07]
|
| |
|
Description:
The Company engages in the development and commercialization of oral drugs to treat infectious diseases.
|
| |
|
Officers:
Eric L. Sorkin (Chair, Pres. & CEO); Cecilia Chan (Dir.); Gary C. Parks (CFO, Treas. & Sec.); Carol Ann Olson, MD, Ph.D. (SVP & Chief Medical Officer); Judy Lau (Dir.); Levi H.K. Lee, MD (Dir.); Donald F. Sinex (Dir.)
|
| |
|
Auditor:
Deloitte & Touche LLP
|
| |
|
Securities:
Common Stock-Symbol IMM; AMEX;
15,374,334 common shares outstanding as of June 9, 2007.
|
| |
| |
| |
| return to main page |
|
|
